Peptides and Cortisol: GHRP Effects on the HPA Axis and Stress Hormones

Cortisol — the primary glucocorticoid produced by the adrenal cortex — is not simply the "stress hormone" popular media portrays. It is an essential regulator of immune function, metabolism, blood pressure, memory, and circadian rhythm. Peptides interact with the HPA (hypothalamic-pituitary-adrenal) axis in profoundly different ways depending on their class. Some amplify cortisol secretion as a secondary effect. Others specifically dampen stress-axis reactivity. Understanding these distinctions shapes both protocol design and clinical outcomes.

The HPA Axis: A Quick Primer

Cortisol is regulated through a negative feedback cascade:

1. The hypothalamus releases corticotropin-releasing hormone (CRH)
2. CRH stimulates the pituitary to release adrenocorticotropic hormone (ACTH)
3. ACTH signals the adrenal cortex to produce and release cortisol
4. Rising cortisol suppresses CRH and ACTH production — completing the feedback loop

This axis is tightly regulated and sensitive to disruption. Chronically elevated cortisol suppresses immune function, degrades lean tissue, impairs memory consolidation, disrupts sleep architecture, and creates insulin resistance. Chronically insufficient cortisol produces fatigue, immune dysregulation, and orthostatic hypotension.

GHRPs and Cortisol: The Mechanism Behind the Elevation

Ghrelin receptors (GHS-R1a) are expressed not just in the pituitary somatotrophs that release GH, but also in the hypothalamus, adrenal glands, and corticotroph cells of the pituitary. When a GHRP binds GHS-R1a in these extra-pituitary locations, it stimulates ACTH release — which in turn drives cortisol secretion from the adrenal cortex.

This is not a side effect of pharmacological excess. It is a physiological property of ghrelin itself. The body's endogenous ghrelin, released during fasting and exercise, naturally co-stimulates both GH and cortisol as part of an integrated metabolic stress response.

Cortisol elevation by peptide

GHRP-6: Produces the most pronounced cortisol co-stimulation of the common GHRPs. Multiple human studies have measured ACTH and cortisol elevations of 50–150% above baseline following acute administration. The cortisol peak generally mirrors the GH peak timing (30–45 minutes post-injection) and returns to baseline within 2–3 hours.

GHRP-2: Similar mechanism to GHRP-6 with somewhat less cortisol elevation per unit dose. Still clinically significant at high doses.

Hexarelin: The most potent GHRP by GH release per dose; also produces meaningful cortisol elevations, though some data suggest the ratio of GH to cortisol stimulation is more favorable than GHRP-6.

Ipamorelin: The standout exception. Ipamorelin was specifically engineered to be selective for pituitary somatotrophs — it has minimal binding affinity for the cortisol-stimulating pathways. Multiple head-to-head studies confirm that ipamorelin produces negligible cortisol or ACTH elevation at therapeutic doses. This is a primary reason ipamorelin is the preferred GHRP for clinical use.

CJC-1295 / Sermorelin / GHRH analogs: GHRH analogs work via a completely different receptor (GHRH-R) that has no direct connection to the HPA axis. These peptides do not stimulate cortisol. If you are exclusively using GHRH analogs without a GHRP, cortisol elevation is not a concern.

Does Repeated GHRP Use Chronically Elevate Cortisol?

The acute cortisol elevation following GHRP injection is transient. The practical concern is what happens with multiple daily injections over months:

In most protocols, the cortisol elevations are brief (2–3 hours) and occur 2–3 times daily at most. Between injections, cortisol returns to baseline. Studies examining longer-term GHRP use do not consistently show sustained elevation of 24-hour cortisol AUC (area under the curve) — suggesting the pulses are not additive in a clinically damaging way.

However, this is context-dependent. Individuals who are already in a high-cortisol state from chronic stress, sleep deprivation, or caloric restriction may experience compounding effects. For these individuals, choosing ipamorelin over GHRP-6 is especially relevant.

Selank: The Anxiolytic Peptide That Reduces HPA Axis Reactivity

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic analog of the endogenous immunomodulatory peptide tuftsin. Developed at the Institute of Molecular Genetics in Russia, it has a distinct mechanism of action from GHRPs and operates in a manner that reduces, rather than elevates, stress axis activity.

How Selank dampens cortisol

Selank modulates GABA-A receptor function (similar to benzodiazepines but without dependence liability), increases BDNF expression in the hippocampus and prefrontal cortex, and reduces the release of stress-induced pro-inflammatory cytokines. Crucially, Selank appears to reduce HPA axis reactivity by:

• Decreasing CRH sensitivity in the hypothalamus
• Normalizing the stress-induced amplification of ACTH release
• Reducing basal and stress-induced cortisol in animal models of chronic stress

Human studies and clinical reports from Russian psychiatric medicine indicate Selank reduces anxiety, stabilizes mood, and produces a measurable reduction in self-reported and biomarker-measured stress without sedation or cognitive impairment.

Selank dosing and administration

Typical research dosing: 250–500mcg administered intranasally or subcutaneously. The intranasal route is notable for rapidity of CNS action. Effects are typically felt within 30–60 minutes.

Intranasal Selank avoids first-pass metabolism and delivers the peptide directly to the olfactory epithelium with direct access to the CNS — making it an efficient route for its anxiolytic and cortisol-modulating effects.

Semax and the Stress Axis

Semax, another Russian-developed nootropic peptide (a fragment of ACTH), acts on melanocortin receptors and increases BDNF, but its relationship with cortisol is more complex. Because it is structurally derived from ACTH, there was initial concern about cortisol stimulation. At typical nootropic doses (200–600mcg intranasally), Semax does not appear to significantly elevate cortisol in available data — but individuals with adrenal hypersensitivity should monitor.

BPC-157 and the HPA Axis

BPC-157 (Body Protection Compound) modulates the dopaminergic and serotonergic systems and has demonstrated in animal models the ability to normalize corticosterone (the rodent equivalent of cortisol) in chronic stress models. It does not directly stimulate or suppress the HPA axis but appears to buffer stress-induced hormonal dysregulation through indirect CNS mechanisms.

Practical Protocol Considerations

Matching peptide selection to cortisol burden

If you are under significant life stress, running a caloric deficit, or have a history of HPA axis dysregulation (including adrenal fatigue patterns), prioritizing ipamorelin over GHRP-6 or GHRP-2 is the most practical adjustment. The GH-releasing efficacy is meaningfully lower with ipamorelin alone, but the absence of cortisol co-stimulation is often worth the trade-off.

Timing to minimize cortisol impact

Morning cortisol naturally peaks at roughly 8am (the cortisol awakening response). Injecting GHRPs at this time adds a pharmacological ACTH surge on top of an already elevated baseline. Evening or pre-sleep dosing is therefore preferable for individuals concerned about cortisol: cortisol is naturally at its nadir before midnight, limiting the additive burden from GHRP-stimulated ACTH.

Stacking Selank with GHRPs

Some advanced users combine Selank with GHRP-containing protocols to offset the cortisol-stimulating effects of the GHRP. The rationale is mechanistically sound — GHRP elevates cortisol through ACTH stimulation, Selank blunts HPA axis reactivity. Whether the combination fully neutralizes the GHRP-cortisol effect in humans has not been directly studied, but the pharmacological logic is reasonable for high-stress individuals.

Monitoring Cortisol Status

For peptide users concerned about cortisol, these tests provide useful data:

• AM serum cortisol (7–9am): Reference range typically 10–20 mcg/dL. Below 7 warrants investigation; above 25 chronically warrants assessment.
• 4-point salivary cortisol testing: Captures the full diurnal pattern (morning, noon, afternoon, evening). This is more informative than a single AM draw for assessing HPA rhythm.
• DHEA-S: The ratio of cortisol to DHEA reflects adrenal "allocation." Low DHEA-S with high cortisol indicates catabolic stress state.
• 24-hour urinary free cortisol: Best for assessing total cortisol burden rather than a snapshot.

Frequently Asked Questions

Q: Will using GHRP-6 cause chronic cortisol elevation? The acute cortisol spikes are real, but 24-hour cortisol burden does not appear to be chronically elevated with typical 2–3x daily GHRP dosing in healthy individuals. Individual variation matters significantly — those with pre-existing HPA axis dysregulation are at higher risk.

Q: Is Selank safe to use daily long-term? Selank has a strong safety profile in available Russian clinical data going back decades. It is non-addictive and does not produce dependence. Typical protocols run 10–14 days on with 1–2 week breaks, though some users run it continuously. No serious adverse events have been reported in clinical literature.

Q: Can peptides help adrenal fatigue? This depends entirely on the peptide. GHRPs may worsen adrenal fatigue patterns by adding cortisol stimulus burden. BPC-157 and Selank may support HPA normalization. Thymosin alpha-1 has immune-regulatory effects that can reduce the chronic immune activation that often drives HPA dysfunction.

Q: Does cortisol elevation from GHRPs blunt the anabolic effects of the GH pulse? In theory, cortisol is catabolic and opposes the anabolic GH/IGF-1 signal. In practice, the transient cortisol elevation from GHRPs does not appear to materially blunt muscle anabolism at typical doses, but it is a meaningful consideration for very high-dose GHRP protocols.

Q: How does ipamorelin compare to GHRP-2 for someone with high baseline cortisol? Ipamorelin is clearly preferable. Its selective GH release without meaningful ACTH co-stimulation makes it the appropriate choice for individuals whose cortisol is already elevated from stress, sleep problems, or metabolic dysfunction.

---

Monitor cortisol patterns alongside your peptide protocols with Optimize to correlate HPA axis changes with protocol adjustments.

Related Articles

• Selank Peptide Guide
• Ipamorelin Peptide Guide
• GHRP-2 Peptide Guide
• Peptides for Adrenal Fatigue
• Peptide Stack for Stress and Burnout